Literature DB >> 28202754

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.

Yudong Quan1, Hongtao Xu1, Yingshan Han1, Thibault Mesplède1, Mark A Wainberg2,1.   

Abstract

HIV can spread by both cell-free and cell-to-cell transmission. Here, we show that many of the amino acid changes in Env that are close to the CD4 binding pocket can affect HIV replication. We generated a number of mutant viruses that were unable to infect T cells as cell-free viruses but were nevertheless able to infect certain T cell lines as cell-associated viruses, which was followed by reversion to the wild type. However, the activation of JAK-STAT signaling pathways caused the inhibition of such cell-to-cell infection as well as the reversion of multiple HIV Env mutants that displayed differences in their abilities to bind to the CD4 receptor. Specifically, two T cell activators, interleukin-2 (IL-2) and phorbol 12-myristate 13-acetate (PMA), both capable of activation of JAK-STAT pathways, were able to inhibit cell-to-cell viral transmission. In contrast, but consistent with the above result, a number of JAK-STAT and mTOR inhibitors actually promoted HIV-1 transmission and reversion. Hence, JAK-STAT signaling pathways may differentially affect the replication of a variety of HIV Env mutants in ways that differ from the role that these pathways play in the replication of wild-type viruses.IMPORTANCE Specific alterations in HIV Env close to the CD4 binding site can differentially change the ability of HIV to mediate infection for cell-free and cell-associated viruses. However, such differences are dependent to some extent on the types of target cells used. JAK-STAT signaling pathways are able to play major roles in these processes. This work sheds new light on factors that can govern HIV infection of target cells.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Env mutant; HIV-1; cell dependence; cell-associated viruses; reversion

Mesh:

Substances:

Year:  2017        PMID: 28202754      PMCID: PMC5391463          DOI: 10.1128/JVI.00075-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

Review 1.  The CD4 antigen: physiological ligand and HIV receptor.

Authors:  Q J Sattentau; R A Weiss
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

2.  Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis.

Authors:  Ana C Tuyama; Feng Hong; Yedidya Saiman; Chuansheng Wang; Derya Ozkok; Arevik Mosoian; Ping Chen; Benjamin K Chen; Mary E Klotman; Meena B Bansal
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

3.  IFITM-Family Proteins: The Cell's First Line of Antiviral Defense.

Authors:  Charles C Bailey; Guocai Zhong; I-Chueh Huang; Michael Farzan
Journal:  Annu Rev Virol       Date:  2014-11-01       Impact factor: 10.431

4.  Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Dror Kolodkin-Gal; Sandrine L Hulot; Birgit Korioth-Schmitz; Randi B Gombos; Yi Zheng; Joshua Owuor; Michelle A Lifton; Christian Ayeni; Robert M Najarian; Wendy W Yeh; Mohammed Asmal; Gideon Zamir; Norman L Letvin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

5.  HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes.

Authors:  Kosuke Miyauchi; Yuri Kim; Olga Latinovic; Vladimir Morozov; Gregory B Melikyan
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

6.  Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies.

Authors:  Irene A Abela; Livia Berlinger; Merle Schanz; Lucy Reynell; Huldrych F Günthard; Peter Rusert; Alexandra Trkola
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

Review 7.  IFITM proteins-cellular inhibitors of viral entry.

Authors:  Se Smith; S Weston; P Kellam; M Marsh
Journal:  Curr Opin Virol       Date:  2014-01-28       Impact factor: 7.090

8.  Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.

Authors:  Ahidjo Ayouba; Claude Cannou; Marie-Thérèse Nugeyre; Françoise Barré-Sinoussi; Elisabeth Menu
Journal:  Retrovirology       Date:  2008-03-31       Impact factor: 4.602

9.  IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.

Authors:  Jingyou Yu; Minghua Li; Jordan Wilkins; Shilei Ding; Talia H Swartz; Anthony M Esposito; Yi-Min Zheng; Eric O Freed; Chen Liang; Benjamin K Chen; Shan-Lu Liu
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

10.  Identification of an endocytic signal essential for the antiviral action of IFITM3.

Authors:  Rui Jia; Fengwen Xu; Jin Qian; Yunfang Yao; Chunhui Miao; Yi-Min Zheng; Shan-Lu Liu; Fei Guo; Yunqi Geng; Wentao Qiao; Chen Liang
Journal:  Cell Microbiol       Date:  2014-02-13       Impact factor: 3.715

View more
  3 in total

1.  Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Authors:  Rachel Van Duyne; Lillian S Kuo; Phuong Pham; Ken Fujii; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

2.  Ubiquitinated Hepatitis D Antigen-Loaded Microvesicles Induce a Potent Specific Cellular Immune Response to Inhibit HDV Replication in Vivo.

Authors:  Ting Yao; Mengjiao Lv; Siyuan Ma; Jinmei Chen; Yi Zhang; Yongsheng Yu; Guoqing Zang; Xiaohua Chen
Journal:  Microbiol Spectr       Date:  2021-12-15

3.  In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.

Authors:  Jiongjiong Wang; Richard A Prinz; Xiufan Liu; Xiulong Xu
Journal:  Viruses       Date:  2020-10-08       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.